[go: up one dir, main page]

ES8601700A1 - Un metodo para tratar un concentrado del factor ix de coagulacion de la sangre - Google Patents

Un metodo para tratar un concentrado del factor ix de coagulacion de la sangre

Info

Publication number
ES8601700A1
ES8601700A1 ES538802A ES538802A ES8601700A1 ES 8601700 A1 ES8601700 A1 ES 8601700A1 ES 538802 A ES538802 A ES 538802A ES 538802 A ES538802 A ES 538802A ES 8601700 A1 ES8601700 A1 ES 8601700A1
Authority
ES
Spain
Prior art keywords
concentrate
factor
plasma
blood coagulation
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES538802A
Other languages
English (en)
Other versions
ES538802A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cedars Sinai Medical Center
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23490802&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES8601700(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Publication of ES538802A0 publication Critical patent/ES538802A0/es
Publication of ES8601700A1 publication Critical patent/ES8601700A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
    • A61L2/04—Heat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
    • A61L2/08—Radiation
    • A61L2/12—Microwaves
    • A61L2103/05—
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

METODO PARA TRATAR UN CONCENTRADO DEL FACTOR IX DE COAGULACION DE LA SANGRE. COMPRENDE: LIOFILIZAR UN CONCENTRADO DEL FACTOR IX DE COAGULACION DE LA SANGRE, SEGUIDO DE CALENTAMIENTO DEL CONCENTRADO DEL FACTOR IX DE COAGULACION DE LA SANGRE A UNA TEMPERATURA PREDETERMINADA DE 60C, DURANTE UN PERIODO DE TIEMPO PARA CONVERTIR EN NO INFECCIOSO AL VIRUS DE LA HEPATITIS NO DE TIPO A, AL VIRUS DE LA HEPATITIS NO DE TIPO B, A UN VIRUS RELACIONADO CON EL CITOMEGALOVIRUS DEL SINDROME DE INMUNODEFICIENCIA ADQUIRIDA (AIDS) O AL VIRUS EPTSTEIN-BARR, PRESENTES EN EL CONCENTRADO DEL FACTOR IX DE COAGULACION DE LA SANGRE. SE EMPLEA UN CONCENTRADO ESENCIALMENTE EXENTO DE LOS FACTORES II, VII, X, XII Y XIII O SUS FORMAS ACTIVAS, QUE TIENE UNA RELACION DE UNIDADES ANTIHEMOFIILICAS DE CUALQUIER ENZIMA DE COAGULACION DE LA SANGRE DE 10:1 A 500:1, Y DONDE EL FACTOR ANTIHEMOFILICO ESTA PURIFICADO HASTA UNA ACTIVIDAD POR PESO UNITARIO DE PROTEINA MAYOR QUE LA CONCENTRACION DEL FACTOR EN EL PLASMA HUMANO NORMAL.
ES538802A 1982-05-13 1984-12-19 Un metodo para tratar un concentrado del factor ix de coagulacion de la sangre Expired ES8601700A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06377863 US4456590B2 (en) 1981-11-02 1982-05-13 Heat treatment of lyphilized blood clotting factor viii concentrate

Publications (2)

Publication Number Publication Date
ES538802A0 ES538802A0 (es) 1985-11-01
ES8601700A1 true ES8601700A1 (es) 1985-11-01

Family

ID=23490802

Family Applications (5)

Application Number Title Priority Date Filing Date
ES522310A Granted ES522310A0 (es) 1982-05-13 1983-05-12 Un metodo de tratar una composicion sustancialmente seca que incluye factor viii de plasma sanguineo.
ES535745A Granted ES535745A0 (es) 1982-05-13 1984-09-07 Un metodo de producir una vacuna para la hepatitis
ES538802A Expired ES8601700A1 (es) 1982-05-13 1984-12-19 Un metodo para tratar un concentrado del factor ix de coagulacion de la sangre
ES538803A Granted ES538803A0 (es) 1982-05-13 1984-12-19 Un metodo para tratar un concentrado de fibrinogeno
ES538801A Expired ES8601699A1 (es) 1982-05-13 1984-12-19 Un metodo para tratar un concentrado del factor viii de coagulacion de la sangre

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ES522310A Granted ES522310A0 (es) 1982-05-13 1983-05-12 Un metodo de tratar una composicion sustancialmente seca que incluye factor viii de plasma sanguineo.
ES535745A Granted ES535745A0 (es) 1982-05-13 1984-09-07 Un metodo de producir una vacuna para la hepatitis

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES538803A Granted ES538803A0 (es) 1982-05-13 1984-12-19 Un metodo para tratar un concentrado de fibrinogeno
ES538801A Expired ES8601699A1 (es) 1982-05-13 1984-12-19 Un metodo para tratar un concentrado del factor viii de coagulacion de la sangre

Country Status (19)

Country Link
US (1) US4456590B2 (es)
EP (2) EP0171506B1 (es)
JP (1) JPS58213721A (es)
AR (1) AR230186A1 (es)
AT (1) AT392905B (es)
AU (3) AU554282B2 (es)
BE (1) BE896724A (es)
BR (1) BR8302504A (es)
CA (1) CA1203165A (es)
CH (1) CH665125A5 (es)
DE (3) DE3382716T2 (es)
DK (1) DK171796B1 (es)
ES (5) ES522310A0 (es)
FR (1) FR2526660B1 (es)
GB (2) GB2120254B (es)
IE (1) IE55008B1 (es)
LU (1) LU84804A1 (es)
MX (1) MX172861B (es)
ZA (1) ZA833315B (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4495278A (en) * 1981-04-27 1985-01-22 Baxter Travenol Laboratories, Inc. Process for making novel blood clotting enzyme compositions
US4994438A (en) * 1981-11-02 1991-02-19 Cedars Sinai Medical Center Heat treatment of lyophilized plasma fractions
US4456590B2 (en) * 1981-11-02 1989-05-30 Heat treatment of lyphilized blood clotting factor viii concentrate
DE3230849A1 (de) * 1982-08-19 1984-02-23 Behringwerke Ag, 3550 Marburg Pasteurisiertes human-fibrinogen (hf) und verfahren zu dessen herstellung
ZA838856B (en) * 1982-12-02 1984-07-25 Usv Pharma Corp Hepatitis b and non-a-non-b-safe biological products
US4615886A (en) * 1983-08-31 1986-10-07 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Utilizing a halohydrocarbon containing dissolved water to inactivate a lipid virus
JPS6054287B2 (ja) * 1983-10-19 1985-11-29 株式会社ミドリ十字 血漿蛋白の加熱処理方法
US4490361A (en) * 1983-12-02 1984-12-25 Alpha Therapeutic Corporation Virus inactivating heat treatment of plasma fractions
AT389815B (de) * 1984-03-09 1990-02-12 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
AT385657B (de) * 1984-03-09 1988-05-10 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
ATE89569T1 (de) * 1984-03-23 1993-06-15 Baxter Int Haemoglobin mit reduziertem virusrisiko und dessen herstellung.
US4831012A (en) * 1984-03-23 1989-05-16 Baxter International Inc. Purified hemoglobin solutions and method for making same
US5281579A (en) * 1984-03-23 1994-01-25 Baxter International Inc. Purified virus-free hemoglobin solutions and method for making same
NL8401066A (nl) * 1984-04-04 1985-11-01 Stichting Centraal Lab Werkwijze ter bereiding van preparaten, die de humorale en cellulaire immuunreaktiviteit vergroten.
US5185160A (en) * 1984-06-21 1993-02-09 Prp, Inc. Platelet membrane microvesicles
JPH0669961B2 (ja) * 1984-09-25 1994-09-07 株式会社ミドリ十字 免疫グロブリンの加熱処理方法
AT390001B (de) * 1984-09-28 1990-03-12 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern
AT390373B (de) * 1984-10-02 1990-04-25 Schwab & Co Gmbh Verfahren zur pasteurisation von plasmaproteinen bzw. von plasmaproteinfraktionen
DE3577801D1 (de) * 1985-08-05 1990-06-28 Immuno Ag Verfahren zur herstellung von praeparationen auf basis von blutgerinnungsfaktoren.
CA1276563C (en) * 1985-09-30 1990-11-20 Stanley E. Charm High temperature, short time heating system and method of sterilizing heat-sensitive biological fluids
EP0225581A3 (en) * 1985-11-30 1989-05-24 Green Cross Corporation Method for the heat-treatment of immunoglobulins and immunoglobulin product
DK595285D0 (da) * 1985-12-20 1985-12-20 Nordisk Gentofte Injicerbart og varmebehandet igg-praeparat og fremgangsmaade til fremstilling af samme
DK155886D0 (da) * 1986-04-04 1986-04-04 Bo Arne Hofmann Vaccine og fremgangsmaade til fremstilling af denne
AT391808B (de) * 1986-11-03 1990-12-10 Immuno Ag Verfahren zur herstellung einer faktor viii (ahf)-haeltigen fraktion
US5099002A (en) * 1987-05-15 1992-03-24 University Of Southern California Sequential improved method for treatment of human blood-clotting factor products
WO1988008710A1 (en) * 1987-05-15 1988-11-17 Rubinstein Alan I Sequential improved method for treatment of human blood-clotting factor products
US5118795A (en) * 1987-05-15 1992-06-02 University Of Southern California Sequential heat treatment of blood-clotting factor products
US5097018A (en) * 1988-05-12 1992-03-17 University Of Southern California Sequential heat treatment of blood-clotting factor products
US4876241A (en) * 1987-05-22 1989-10-24 Armour Pharmaceutical Company Stabilization of biological and pharmaceutical products during thermal inactivation of viral and bacterial contaminants
US4861867A (en) * 1988-02-03 1989-08-29 Baxter International, Inc. Purified hemoglobin solutions and method for making same
DE69011136T3 (de) * 1989-01-13 2003-10-23 Mitsubishi Pharma Corp Verfahren zur Herstellung einer Protein enthaltenden Zusammensetzung.
US5332578A (en) * 1989-04-14 1994-07-26 Prp, Inc. Platelet membrane microparticles
AT402891B (de) * 1991-06-20 1997-09-25 Immuno Ag Verfahren zur herstellung eines inaktivierten blutproduktes
AT399818B (de) * 1992-04-24 1995-07-25 Immuno Ag Verfahren zur herstellung einer hochgereinigten virussicheren faktor viii-präparation
JPH06166634A (ja) * 1992-12-01 1994-06-14 Green Cross Corp:The プラスミノーゲン含有組成物の製造方法
EP0674531A1 (de) * 1992-12-16 1995-10-04 IMMUNO Aktiengesellschaft Verfahren zur herstellung eines virussicheren biologischen präparates
DE4320294A1 (de) * 1993-06-18 1994-12-22 Immuno Ag Verwendung von humanem Protein C zur Verhinderung und Behandlung von Thrombozytenablagerungen
DE4404625C2 (de) * 1994-02-14 1996-10-17 Ludwig Dr Baumgartner Verfahren zur Inaktivierung thermolabiler Viren in biologischem Material unter Beibehaltung der kollagenen Eigenschaften
US20030143518A1 (en) * 1994-11-18 2003-07-31 Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. Method of drying blood plasma
DE4441167C1 (de) * 1994-11-18 1996-03-14 Fraunhofer Ges Forschung Verfahren zur Trocknung von Blutplasma
GB9424732D0 (en) * 1994-12-08 1995-02-08 Common Services Agency Heat treated blood plasma proteins
US5741894A (en) * 1995-09-22 1998-04-21 Baxter International, Inc. Preparation of pharmaceutical grade hemoglobins by heat treatment in partially oxygenated form
US5659017A (en) * 1995-11-07 1997-08-19 Alpha Therapeutic Corporation Anion exchange process for the purification of Factor VIII
US6632648B1 (en) * 1996-05-14 2003-10-14 Elan Drug Delivery Limited Methods of terminal sterilization of fibrinogen
DE19623293C2 (de) * 1996-06-11 1998-10-22 Biotest Pharma Gmbh Nicht-immunogene Faktor VIII-enthaltende Zusammensetzung und ein Verfahren zu ihrer Herstellung
US5837519A (en) * 1996-11-21 1998-11-17 Bayer Corporation Dry-heat viral inactivation under controlled moisture conditions
EP2130554B1 (en) 1999-02-22 2012-09-05 University of Connecticut Albumin-free factor VIII formulations
JP4663837B2 (ja) * 1999-12-24 2011-04-06 一般財団法人化学及血清療法研究所 第▲ｖｉｉｉ▼因子を主成分とする血小板減少に伴う出血疾患の予防・治療用医薬組成物
RU2174841C1 (ru) * 2000-06-06 2001-10-20 Российский научно-исследовательский институт гематологии и трансфузиологии Способ получения пула нормальной плазмы
FR2857267B1 (fr) 2003-07-09 2006-03-10 Lab Francais Du Fractionnement Formulation stabilisante et solubilisante pour les proteines cryoprecipitables.
EP2278002B1 (en) 2005-07-29 2017-07-12 Abbott Laboratories GmbH Pancreatin with reduced viral content
FR2894830B1 (fr) 2005-12-19 2008-04-04 Lab Francais Du Fractionnement Procede d'inactivation virale par chauffage a sec selon la temperature de transition vitreuse
BRPI0921429B1 (pt) 2008-11-07 2022-07-12 Takeda Pharmaceutical Company Limited Formulação farmacêutica liofilizada estável, e, método para preparar um fator liofilizado estável
EP3694322B1 (en) 2017-10-09 2024-07-03 Terumo BCT Biotechnologies, LLC Lyophilization container and method of using same
JP7541993B2 (ja) 2019-03-14 2024-08-29 テルモ ビーシーティー バイオテクノロジーズ，エルエルシー 凍結乾燥用ローディングトレイ組立体、凍結乾燥システム及び凍結乾燥方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3100737A (en) * 1958-02-05 1963-08-13 Auerswald Wilhelm Method of preparing a plasma protein solution free of active hepatitis virus and product produced thereby
US3041242A (en) * 1958-06-17 1962-06-26 Sr Courtland H Barr Gas and heat sterilization of dried human plasma
US3859168A (en) * 1967-06-22 1975-01-07 Behringwerke Ag Process of inactivating rabies virus
DE1617350C3 (de) * 1967-06-22 1979-09-06 Behringwerke Ag, 3550 Marburg Verfahren zur Inaktivierung von biologischem Material
US3579631A (en) * 1968-05-21 1971-05-18 Aubrey P Stewart Jr Sterilization of materials containing protein
GB1471336A (en) * 1973-04-16 1977-04-21 Armour Pharma Process for the purification and sterilisation of acidophilic biologicals-
US3998516A (en) * 1973-05-15 1976-12-21 Mabuchi Motor Co. Ltd. Adapter
JPS6015B2 (ja) * 1977-07-16 1985-01-05 株式会社新潟鐵工所 水溶性かつ熱凝固性を有する殺菌された血粉の製造方法
US4250139A (en) * 1979-02-01 1981-02-10 Collagen Corporation Microwave sterilization of dry protein
DE2916711A1 (de) * 1979-04-25 1980-11-06 Behringwerke Ag Blutgerinnungsfaktoren und verfahren zu ihrer herstellung
JPS56135418A (en) * 1980-03-27 1981-10-22 Green Cross Corp:The Heat treatment of aqueous solution containing 8 factor of coagulation of blood derived from human
DE3043857A1 (de) * 1980-11-21 1982-07-08 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung von blutgerinnungsfaktoren und danach hergestellte praeparation der faktoren ii und vii
DE3045153A1 (de) * 1980-11-29 1982-07-08 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung von blutgerinnungsfaktoren und danach hergestellte praeparation der faktoren ix und x
JPS57140724A (en) * 1981-02-25 1982-08-31 Green Cross Corp:The Heat-treatment of aqueous solution containing cold insoluble globulin
US4495278A (en) * 1981-04-27 1985-01-22 Baxter Travenol Laboratories, Inc. Process for making novel blood clotting enzyme compositions
US4456590B2 (en) * 1981-11-02 1989-05-30 Heat treatment of lyphilized blood clotting factor viii concentrate

Also Published As

Publication number Publication date
ES538801A0 (es) 1985-11-01
EP0094611A3 (en) 1984-08-22
DK210283A (da) 1983-11-14
ZA833315B (en) 1984-01-25
EP0094611B1 (en) 1986-06-11
ES8501627A1 (es) 1984-12-01
AU569428B2 (en) 1988-01-28
AU554282B2 (en) 1986-08-14
DE171506T1 (de) 1986-11-06
GB2144428B (en) 1986-03-12
AU1442183A (en) 1983-12-15
BR8302504A (pt) 1983-10-25
JPS58213721A (ja) 1983-12-12
DE3382716T2 (de) 1994-03-31
AU5765986A (en) 1986-10-09
CH665125A5 (de) 1988-04-29
BE896724A (fr) 1983-09-01
ATA176783A (de) 1985-10-15
ES538802A0 (es) 1985-11-01
US4456590B1 (es) 1989-01-03
ES8601699A1 (es) 1985-11-01
ES8601701A1 (es) 1985-11-01
FR2526660B1 (fr) 1987-11-20
DK210283D0 (da) 1983-05-11
GB2120254A (en) 1983-11-30
DE3382716D1 (de) 1993-10-28
AU5766086A (en) 1986-10-30
ES538803A0 (es) 1985-11-01
GB8312915D0 (en) 1983-06-15
ES8505821A1 (es) 1985-06-16
US4456590A (en) 1984-06-26
IE55008B1 (en) 1990-04-25
EP0171506B1 (en) 1993-09-22
CA1203165A (en) 1986-04-15
DE3364057D1 (en) 1986-07-17
MX172861B (es) 1994-01-17
AU568979B2 (en) 1988-01-14
EP0171506A1 (en) 1986-02-19
ES535745A0 (es) 1985-06-16
FR2526660A1 (fr) 1983-11-18
LU84804A1 (fr) 1983-11-17
US4456590B2 (en) 1989-05-30
AR230186A1 (es) 1984-03-01
GB2144428A (en) 1985-03-06
EP0094611A2 (en) 1983-11-23
AT392905B (de) 1991-07-10
DK171796B1 (da) 1997-06-02
GB2120254B (en) 1984-06-20
GB8332374D0 (en) 1984-01-11
ES522310A0 (es) 1984-12-01
IE831068L (en) 1983-11-13

Similar Documents

Publication Publication Date Title
ES8601700A1 (es) Un metodo para tratar un concentrado del factor ix de coagulacion de la sangre
DK184186A (da) Terapeutisk praeparat til behandling af virussygdomme
DE69233631D1 (de) 1,3-Oxathiolane zur Behandlung von Hepatitis
ATE157251T1 (de) Verwendung von inositoltriphosphat zur behandlung von entzündungen
FI946004A0 (fi) Lääketieteellisessä toimenpiteessä käytettävä trombiiniverifraktio
ES2150496T3 (es) Cicloalquilimidazopiridinas condensadas.
ES2186714T3 (es) Uso de sustipo simple alpha 8 en la preparacion de medicamentos para el tratamiento de infecciones virales del higado.
ATE71843T1 (de) Behandlung des atemunwohlseinsyndroms bei erwachsenen.
DE69025834D1 (de) Antivirale Verbindungen
ES2042751T3 (es) Nuevo procedimiento para la purificacion de viriones de la hepatitis a.
ES2033880T3 (es) Pasteurizacion de soluciones de inmunoglobulinas.
ATE77554T1 (de) Pharmazeutisches praeparat mit 3'-desoxythymidin2'-en(3'-desoxy-2',3'-didehydrothymidin) zur behandlung von patienten mit retroviralen infektionen.
ES2125976T3 (es) Otros derivados de indol con accion antiviral.
ATE85523T1 (de) Taurohyodeoxycholsaeure zur behandlung von gallenwegssteinen und gallenstoerungen.
DE69230643D1 (de) Methode zur behandlung von viralen infektionen
DK472688A (da) Anvendelse af bezafibrat til behandling af diabetes
DK334780A (da) Fremgangsmaade til toerbehandling af spildegasstroemme i spildegasrensningssystemer
ATE115863T1 (de) Verwendung eines immunglobulinhaltigen präparates zur prophylaxe und therapie von aids beim menschen.
ATE121779T1 (de) Nichtzurückschlagende rns-viren.
DK0653939T3 (da) Anvendelse af en Hymenoptera-gift til fremstilling af et medikament til behandling af DNA-virusinfektioner
ES2149791T3 (es) Procedimiento para la inactivacion de virus en preparaciones de proteinas.
ES2166752T3 (es) Asociacion entre un retrovirus relacionado con el virus de inmunodeficiencia humana y el sindrome de sjogren.
ES2052579T3 (es) Empleo de interferon alfa humano recombinante para la fabricacion de un medicamento para tratar el virus del sida.
FI881123A0 (fi) Inaktivering av human immunodeficiency virus (hiv) medelst fenol i proteinhaltiga loesningar.
ATE255417T1 (de) Verwendung von bradykinin-antagonisten zur behandlung von viruserkrankungen

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 20040604